Navigating the Complexity of Alternating Hemiplegia in Childhood: A Comprehensive Review

• Published in: Rambam Maimonides medical journal Vol. 15; no. 3; p. e0015
• Main Authors: Rissardo, Jamir Pitton, Vora, Nilofar Murtaza, Singh, Yogendra, Kishore, Sweta, Caprara, Ana Letícia Fornari
• Format: Journal Article
• Language: English
• Published: Israel Rambam Health Care Campus 30.07.2024
• Subjects: aicardi; alternating hemiplegia of childhood; atp1a2; atp1a3; flunarizine; rare disease; Review
• ISSN: 2076-9172; 2076-9172
• DOI: 10.5041/RMMJ.10529

Alternating hemiplegia of childhood (AHC) is a complex neurodevelopmental disorder characterized by paroxysmal and transient events of unilateral or bilateral paresis, usually occurring before 18 months of age. Mutations in the ATP1A3 gene, mainly p.Asp801Asn, p.Glu815Lys, and p.Gly947Arg at the protein level, are found in around 80% of the individuals with AHC. Interestingly, these mutations reflect the degree of severity of the neurological symptoms (p.Glu815Lys > p.Asp801Asn > p.Gly947Arg). Some channels involved in this disorder are N-type voltage-gated calcium channels, ATP-sensitive potassium channels, and the sodium/calcium exchanger. In this context, the management of AHC should be divided into the treatment of attacks, prophylactic treatment, and management of comorbidities commonly found in this group of individuals, including epilepsy, attention-deficit/hyperactivity disorder, aggressive behavior, cognitive impairment, movement disorders, and migraine. The importance of an integrated approach with a multidisciplinary team, such as neuropsychologists and dietitians, is worth mentioning, as well as the follow-up with a neurologist. In the present study, we propose new diagnostic criteria for AHC, dividing it into clinical, laboratory, supporting, and atypical features. Also, we review the location of the mutations in the ATP1A3 protein of individuals with AHC, rapid-onset dystonia-parkinsonism (RDP) variants, and early infantile epileptic encephalopathy (variants with hemiplegic attack). We also include a section about the animal models for ATP1A3 disorders.